Core Insights - Onco-Innovations Limited's subsidiary, Inka Health Corp., has been selected by OneMedNet Corporation to lead a data analytics initiative aimed at improving cancer therapy market access through the use of external control arms (ECAs) [1][3][5] - The project leverages OneMedNet's regulatory-grade patient data to potentially accelerate treatment access and reduce the costs associated with traditional clinical trials [1][2][3] - The Real-World Evidence (RWE) market is projected to exceed $4.6 billion globally by 2030, indicating significant growth potential for this initiative [1][2] Company Overview - Onco-Innovations Limited is focused on cancer research and treatment, specializing in oncology and aiming to innovate solutions for cancer prevention and treatment [10] - Inka Health utilizes advanced causal AI through its SynoGraph platform to enhance oncology research and drug development, aiming to optimize treatment decisions and clinical trial designs [9] - OneMedNet is revolutionizing Real-World Data (RWD) utilization, providing diverse and longitudinal datasets that support healthcare innovation and regulatory-grade evidence generation [7][8] Project Details - The multi-phase project aims to replicate traditional clinical trial results using OneMedNet's oncology dataset, offering a more efficient path for regulatory and reimbursement approvals [3][4] - The initial focus will be on non-small cell lung cancer (NSCLC), a significant area where real-world insights can improve patient access to therapies [4][5] - The collaboration is expected to produce a scientific abstract for ISPOR Europe 2025, highlighting Inka Health's leadership in applying AI and RWD in oncology [5][6]